SNOW

150.46

-1.9%↓

SNOW

150.46

-1.9%↓

SNOW

150.46

-1.9%↓

SNOW

150.46

-1.9%↓

SNOW

150.46

-1.9%↓

Search

Kilroy Realty Corp

Suletud

SektorKinnisvara

28.18 -0.21

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.85

Max

28.66

Põhinäitajad

By Trading Economics

Sissetulek

114M

276M

Müük

-7.5M

272M

P/E

Sektori keskmine

12.177

57.373

Aktsiakasum

0.1

Dividenditootlus

7.72

Kasumimarginaal

101.433

Töötajad

241

EBITDA

-99M

183M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+28.85% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

7.72%

6.91%

Järgmine tulemuste avaldamine

4. mai 2026

Järgmine dividendimakse kuupäev

8. apr 2026

Järgmine aktsia dividendi kuupäev (ex-date)

29. juuni 2026

Turustatistika

By TradingEconomics

Turukapital

-699M

3.4B

Eelmine avamishind

28.39

Eelmine sulgemishind

28.18

Uudiste sentiment

By Acuity

100%

0%

156 / 167 Pingereas Real estate

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Kilroy Realty Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. märts 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. märts 2026, 23:14 UTC

Market Talk
Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. märts 2026, 21:24 UTC

Market Talk
Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

Võrdlus sarnastega

Hinnamuutus

Kilroy Realty Corp Prognoos

Hinnasiht

By TipRanks

28.85% tõus

12 kuu keskmine prognoos

Keskmine 36.4 USD  28.85%

Kõrge 44 USD

Madal 29 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Kilroy Realty Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

11 ratings

1

Osta

9

Hoia

1

Müü

Tehniline skoor

By Trading Central

30.81 / 32.73Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Kilroy Realty Corp

Kilroy Realty Corporation (NYSE: KRC, the "Company", "Kilroy") is a leading U.S. landlord and developer, with operations in San Diego, Los Angeles, the San Francisco Bay Area, Seattle, and Austin. The Company has earned global recognition for sustainability, building operations, innovation, and design. As a pioneer and innovator in the creation of a more sustainable real estate industry, the Company's approach to modern business environments helps drive creativity and productivity for some of the world's leading technology, entertainment, life science, and business services companies. The Company is a publicly traded real estate investment trust ("REIT") and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring, and managing office, life science, and mixed-use projects. As of June 30, 2024, Kilroy's stabilized portfolio totaled approximately 17.0 million square feet of primarily office and life science space that was 83.7% occupied and 85.4% leased. The Company also had approximately 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 92.8%. In addition, the Company had two in-process life science redevelopment projects totaling approximately 100,000 square feet with total estimated redevelopment costs of $80.0 million, and one approximately 875,000 square foot in-process development project with a total estimated investment of $1.0 billion.
help-icon Live chat